GENERAL CLINICAL RESEARCH CENTER

加州大学洛杉矶分校综合临床研究中心（GCRC）是一个设施， 研究者与批准的协议，从不同的学科， 医学院可以对人体进行研究。本申请 建议继续研究期间建立的整体方向， 最后一次融资。项目经理将继续在同一 领导，我们建议将Hal Morgenstern博士作为主任 流行病学，以进一步促进临床调查的培训。 要求增加患者护理和核心实验室人员， 充分支持议定书数量的增加以及 在未来的预期。我们计划增加教育活动 通过GCRC为医学生，研究员和初级教师; CAP 而MCAP获奖者也将参与这些活动。核心 博士课程临床研究学位将被开发 对于医学院的学员，CAP和MCAP获奖者将 成为潜在的参与者。预计， 包括住院病人和门诊病人未来5年，45 来自医学系的不同主要研究者， 儿科、外科、矫形外科、精神病学、产科和 妇科，眼科，分子和医学药理学将进行 各种各样的研究方案其中一些研究将包括： 成人和儿童患者的艾滋病/艾滋病毒相关方案;基因治疗 对于黑色素瘤和神经母细胞瘤， 拟在下次资助期间开展; NIDDM的分子基础; 儿科癫痫发作疾病管理的多种策略; 成人和儿童终末期代谢性骨病患者 肾病;与全胃肠外营养相关的骨病; 骨髓移植治疗癌症并发骨质减少 在临床上;治疗卵巢和乳腺癌的新策略 癌症;原发性甲状旁腺癌患者甲状旁腺功能的评估 和继发性甲状旁腺功能亢进;通过 骨化三醇和重组人生长激素在透析儿童中的应用;骨 儿童肾移植受者疾病;妇女健康 前瞻性研究;消化道出血的前瞻性研究 溃疡，马洛里韦斯和Dieulafoy病损;动脉粥样硬化脂质， 脂蛋白和钙化;激素干预儿童 矮小;青霉胺与系统性硬化症;交感神经 晚期心力衰竭患者的活动。

The UCLA General Clinical Research Center (GCRC) is a facility where investigators with approved protocols from various disciplines in the Medical School could conduct research on human subjects. This application proposes to continue the overall research direction established during the last funding period. The Program Director will continue under the same leadership and we propose to incorporate Dr. Hal Morgenstern, as Director of Epidemiology, to further foster training in clinical investigation. Increased patient care and core laboratory personnel are requested to adequate support the increased number of protocols as well as those anticipated in the future. We plan to increase the education activities through the GCRC for medical students, fellows and junior faculty; the CAP and MCAP awardees will also participate in these activities. A core curriculum for a Ph.D. degree in clinical investigation will be developed for trainees in the School of Medicine and the CAP and MCAP awardees will be potential participants. It is anticipated an increased utilization for both inpatient and outpatient protocols. During the next 5 years, 45 different Principal Investigators from the departments of Medicine, Pediatrics, Surgery, Orthopedic Surgery, Psychiatry, Obstetrics and Gynecology, Ophthalmology, Molecular and Medical Pharmacology will conduct a diversity of research protocols. Some of such studies will include: AIDS/HIV related protocols for adult and pediatric patients; gene therapy for melanoma and neuroblastoma and additional gene therapy protocols will be to carry out during the next funding; molecular basis of NIDDM; multiple strategies for the management of pediatric seizure disorders; metabolic bone diseases in adult and pediatric patients with end-stage renal disease; bone disease associated with total parenteral nutrition; osteopenia as a complication of cancer therapy of bone marrow transplant in clindren; new strategies for the treatment of ovarian and breast cancer; assessment of parathyroid gland function in patients with primary and secondary hyperparathyroidism; regulation of bone formation by calcitriol and recombinant human growth hormone in dialyzed children; bone disease in pediatric renal transplant recipients; women's health initiative study; prospective studies for severe bleeding from peptic ulcer, Mallory Weiss and Dieulafoy's lesion; atherosclerosis lipids, lipoprotein and calcification; hormonal intervention in children with short stature; penicillamine and systemic sclerosis; symphathetic nerve activity in patients with advanced heart failure.